Doctor's DEA Bid Sinks Over Missed Hearing Deadlines
Published Date: 4/16/2025
Notice
Summary
Dr. Moustafa M. Aboshady’s application to register with the DEA in Salt Lake City was denied because he’s barred from federal health programs like Medicare and Medicaid. He asked for a hearing but missed key deadlines to respond properly, so the DEA moved forward without his full defense. This means he can’t legally handle controlled substances, affecting his medical practice and income starting early 2024.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Denied for Dr. Aboshady
The Drug Enforcement Administration denied Moustafa M. Aboshady, M.D.'s pending application for a DEA Certificate of Registration (Control No. W23147064C). The Order denying his application, and any other pending application for additional registration in Utah, is effective May 16, 2025.
Found Excluded from Federal Health Programs
The record shows that HHS/OIG mandatorily excluded Dr. Moustafa M. Aboshady from participation in Medicare, Medicaid, and all Federal health care programs pursuant to 42 U.S.C. 1320a-7(a) for a minimum of 15 years. That exclusion became effective August 30, 2019 and was a basis for the DEA's denial under 21 U.S.C. 824(a)(5).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Previous / Next Documents
Previous: 2025-06425 — Empire Pharmacy Inc.; Skyline Pharmacy Inc.; Decision and Order
Empire Pharmacy and Skyline Pharmacy in Philadelphia lost their DEA registrations because they didn’t keep proper records of controlled substances, which could risk public safety. Their registrations were suspended immediately, and since they didn’t ask for a hearing, the suspension and revocation are now final. This means they can’t legally handle controlled drugs anymore, affecting their business and customers starting now.
Next: 2025-06427 — Lona Bibbs-Walker, D.D.S.; Decision and Order
Dr. Lona Bibbs-Walker's license to handle controlled substances is officially suspended and set for revocation because she lost track of many drugs and lost her state dental license. Since she didn’t ask for a hearing, the DEA is moving forward with shutting down her registrations, protecting public safety. This means she can’t legally prescribe or handle controlled substances anymore, effective immediately.